Physician profile
Harrison D Sciulli
NPI 1356803704
$3,563.50
in general payments reported to CMS, 2019-2025
15 companies · $1,064 in 2025
The $1,064 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $205 · 2022: $387 · 2023: $624 · 2024: $1,283 · 2025: $1,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,512 · Honoraria: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,511.50 |
| Honoraria | $460.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $756.83 | 2023-2024 | Yutiq, Iluvien |
| Genentech USA, INC. | $661.05 | 2022-2025 | Vabysmo, Susvimo |
| Regeneron Healthcare Solutions, INC. | $572.85 | 2022-2025 | Eylea Hd |
| Apellis Pharmaceuticals, INC. | $433.95 | 2024-2025 | Syfovre |
| Abbvie INC. | $235.35 | 2022-2025 | |
| Dutch Ophthalmic, USA | $227.91 | 2024-2025 | Eva, Combined Machine, Tissueblue |
| Alcon Vision LLC | $153.86 | 2023 | Clareon |
| Astrazeneca Pharmaceuticals Lp | $105.34 | 2020 | |
| Allergan, INC. | $99.99 | 2020 | |
| Astellas Pharma US INC | $97.23 | 2023-2025 | Izervay |
| Genentech, INC. | $93.24 | 2024 | Vabysmo |
| Regeneron Pharmaceuticals, INC. | $44.57 | 2025 | Eylea Hd |
| Bausch & Lomb Americas INC. | $40.78 | 2022-2025 | Xipere |
| Harrow Eye, LLC | $20.64 | 2025 | Iheezo |
| Ani Pharmaceuticals, INC. | $19.91 | 2025 | Yutiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harrison Sciulli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.